228 related articles for article (PubMed ID: 6212205)
1. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
Cynamon MH; Granato PA
Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
Verbist L; Verhaegen J
Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
[TBL] [Abstract][Full Text] [Related]
3. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
5. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
Hanslo D; King A; Shannon K; Warren C; Phillips I
J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
[No Abstract] [Full Text] [Related]
6. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.
Cherubin CE; Corrado ML; Sierra MF; Gombert ME; Shulman M
Antimicrob Agents Chemother; 1981 Oct; 20(4):553-5. PubMed ID: 6282200
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.
McNamara BT; Meyer RD; Pasiecznik KA
Antimicrob Agents Chemother; 1982 May; 21(5):753-7. PubMed ID: 6213196
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
Verbist L
Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
O'Donnell ED; Freimer EH; Gilardi GL; Raeder R
Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143
[TBL] [Abstract][Full Text] [Related]
10. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
Corrado ML; Landesman SH; Cherubin CE
Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
Perrymann F; Flournoy DJ; Qadri SM
Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
Pusztai-Markos Z; Pranada F
Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates.
Cohn DL; Reimer LG; Reller LB
J Antimicrob Chemother; 1982 Mar; 9(3):183-94. PubMed ID: 6210653
[No Abstract] [Full Text] [Related]
14. Comparative activities of 13 beta-lactam antibiotics.
Muytjens HL; van der Ros-van de Repe J
Antimicrob Agents Chemother; 1982 Jun; 21(6):925-34. PubMed ID: 7114839
[TBL] [Abstract][Full Text] [Related]
15. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.
Livingston WK; Elliott AM; Cobbs CG
Antimicrob Agents Chemother; 1981 Jan; 19(1):114-6. PubMed ID: 6787975
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.
Cynamon MH; Palmer GS
Antimicrob Agents Chemother; 1982 Dec; 22(6):1079-81. PubMed ID: 6961887
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.
Nasu M; Maskell JP; Williams RJ; Williams JD
Antimicrob Agents Chemother; 1981 Oct; 20(4):433-6. PubMed ID: 6282191
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1982 Jan; 21(1):180-7. PubMed ID: 6979306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
